Moderna (NASDAQ:MRNA) Sees Unusually-High Trading Volume - What's Next?

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shares saw an uptick in trading volume on Tuesday . 2,749,010 shares traded hands during trading, a decline of 48% from the previous session's volume of 5,247,541 shares.The stock last traded at $47.40 and had previously closed at $42.57.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research reports. Oppenheimer lowered Moderna from an "outperform" rating to a "market perform" rating in a report on Friday, September 13th. The Goldman Sachs Group decreased their price target on shares of Moderna from $178.00 to $139.00 and set a "buy" rating on the stock in a research note on Monday, September 16th. Wolfe Research began coverage on shares of Moderna in a research note on Friday, November 15th. They set an "underperform" rating and a $40.00 price objective for the company. Royal Bank of Canada reissued a "sector perform" rating and issued a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Finally, TD Cowen lowered their target price on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a report on Friday, September 13th. Four research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $79.50.

Moderna Price Performance

The company has a market capitalization of $18.29 billion, a price-to-earnings ratio of -8.17 and a beta of 1.60. The company has a fifty day simple moving average of $43.38 and a two-hundred day simple moving average of $71.48. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the company posted ($1.39) EPS. The company's quarterly revenue was up 3.8% compared to the same quarter last year. As a group, research analysts anticipate that Moderna, Inc. will post -9.3 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 over the last 90 days. 15.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of institutional investors have recently modified their holdings of the business. Axiom Advisory LLC grew its holdings in shares of Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company's stock valued at $847,000 after purchasing an additional 198 shares during the last quarter. Redwood Wealth Management Group LLC grew its stake in Moderna by 6.9% during the 2nd quarter. Redwood Wealth Management Group LLC now owns 3,342 shares of the company's stock worth $397,000 after buying an additional 215 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna in the second quarter worth $26,000. Arkadios Wealth Advisors increased its position in Moderna by 2.2% in the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company's stock worth $764,000 after buying an additional 243 shares during the period. Finally, Knuff & Co LLC lifted its stake in Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock valued at $316,000 after buying an additional 244 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.